BASEL, SWITZERLAND--(Marketwire - April 21, 2008) -
* Novartis on track in 2008:
* Net sales from continuing operations up 9% (+0% in local currencies) to USD 9.9 billion with double-digit contributions from Sandoz, Vaccines and Diagnostics and Consumer Health * Operating income rises 7% to USD 2.5 billion, supporting major investments in new product launches, pipeline and emerging markets * Net income up 10% to USD 2.3 billion; EPS advances 15% to USD 1.02
